Global Blood Therapeutics, Inc. (GBT): Price and Financial Metrics
GET POWR RATINGS... FREE!
GBT Stock Price Chart Interactive Chart >
GBT Price/Volume Stats
|Current price||$68.49||52-week high||$73.02|
|Prev. close||$68.48||52-week low||$21.65|
|Day high||$68.49||Avg. volume||2,065,836|
|50-day MA||$62.32||Dividend yield||N/A|
|200-day MA||$38.21||Market Cap||4.62B|
Global Blood Therapeutics, Inc. (GBT) Company Bio
Global Blood Therapeutics is a clinical stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. The company was founded in 2012 and is based in San Francisco, California.
Most Popular Stories View All
GBT Latest News Stream
|Loading, please wait...|
GBT Latest Social Stream
View Full GBT Social Stream
Latest GBT News From Around the Web
Below are the latest news stories about GLOBAL BLOOD THERAPEUTICS INC that investors may wish to consider to help them evaluate GBT as an investment opportunity.
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease PatientsSOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell d
GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference
Keynote by Admiral Rachel Levine, M.D., Assistant Secretary for Health, U.S. Department of Health and Human ServicesSOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 11th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 14th. The virtual conference, which takes place during National Sickle Cell Awareness Mon
Global Blood (GBT) Up 1.9% Since Last Earnings Report: Can It Continue?
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year
Biotech stocks are scorching right now. But the best of the best have strong gains. Those include 10 with at least 40% growth this year.
Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
GBT Price Returns
Loading social stream, please wait...